12.1.31 Receptor signaling protein serine/threonine kinase activity
12.1.32 RNA binding
12.1.33 Structural constituent of cytoskeleton
12.1.34 Superoxide dismutase activity
12.1.35 T cell receptor activity
12.1.36 Transcription factor activity
12.1.37 Transcription regulator activity
12.1.38 Transferase activity
12.1.39 Translation regulator activity
12.1.40 Transmembrane receptor activity
12.1.41 Transmembrane receptor protein tyrosine kinase activity
12.1.42 Transporter activity
13. Apoptopic Drug Target Mix by Development Stage
14. Apoptopic Drug Target Mix by Cancer Indication
14.1 Basal Cell Cancer
14.2 Biliary Cancer
14.3 Bladder Cancer
14.4 Bone Cancer
14.5 Brain Cancer
14.6 Breast Cancer
14.7 Carcinoid Tumor
14.8 Cervical Cancer
14.9 Chemotherapy-induced Neutropenia
14.10 Colorectal Cancer
14.11 Endometrial Cancer
14.12 Fallopian Tube Cancer
14.13 Gastrointestinal Cancer
14.13.1 Gastrointestinal Stomach Cancer
14.13.2 Gastrointestinal Stromal Cancer
14.14 Head and Neck Cancer
14.15 Leukemia
14.15.1 Acute Lymphocytic Leukemia
14.15.2 Acute Myelogenous Leukemia
14.15.3 Chronic Lymphocytic Leukemia
14.15.4 Chronic Myelogenous Leukemia
14.16 Liver Cancer
14.17 Lung Cancer
14.17.1 Non-Small Cell Lung Cancer
14.17.2 Small Cell Lung Cancer
14.18 Lymphoma
14.18.1 B-cell Lymphoma
14.18.2 Hodgkin' s Lymphoma
14.18.3 non-Hodgkin' s Lymphoma
14.18.4 T-cell Lymphoma
14.19 Melanoma
14.20 Mesothelioma
14.21 Myelodysplastic Syndrome
14.22 Myeloma
14.23 Nasopharyngeal Cancer
14.24 Oesophageal Cancer
14.25 Oral Cancer
14.26 Ovarian Cancer
14.27 Pancreatic Cancer
14.28 Peritoneal Cancer
14.29 Prostate Cancer
14.30 Renal Cancer
14.31 Sarcoma
14.31.1 Leiomyo Sarcoma
14.32 Squamous Cell Cancer
14.33 Testicular Cancer
14.34 Thymoma Cancer
14.35 Thyroid Cancer
15. Apoptopic Drugs and their Targets by Companies
15.1 Australia
15.2 Canada
15.3 China
15.4 Denmark
15.5 Germany
15.6 Israel
15.7 Japan
15.8 South Korea
15.9 Spain
15.10 Switzerland
15.11 Taiwan
15.12 United Kingdom
15.13 USA
16. Disclaimer
17. Drug Index
18. Company Index
4.1 List of Figures
Figure 1: Distribution of Compound Types Among Apoptopic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables
Table 1: Compound Type Versus Primary and Alternate Localization of Drug
Target
Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of the Drug Targets
Belonging to Apoptopic Drugs
Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging
to Apoptopic Drugs
Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug
Targets
Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction
with other Drug Targets
Table 13: Number of Available Biological Structures on Apoptopic Drug
Targets
Table 14: Overview of Drug Target Profile Themes
Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and
Developmental Projects by Developmental Stage
Table 16: Apoptopic Drug Target Mixes by Development
Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer
Indication
Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer
According to the Compound Type and Developmental Stage of Drug
Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer
According to the Compound Type and Developmental Stage of Drug
Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer
According to the Compound Type and Developmental Stage of Drug
Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer
According to the Compound Type and Developmental Stage of Drug
Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer
According to the Compound Type and Developmental Stage of Drug
Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer
According to the Compound Type and Developmental Stage of Drug
Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor
According to the Compound Type and Developmental Stage of Drug
Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer
According to the Compound Type Developmental Stage of Drug
Table 26: Apoptopic Drug Target Mix for the Treatment of
Chemotherapy-induced Neutropenia According to Compound Type and Developmental
Stage of Drug
Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer
According to the Compound Type and Developmental Stage of Drug
Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial
Cancer According to the Compound Type and Developmental Stage of Drug
Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube
Cancer According to the Compound Type and Developmental Stage of Drug
Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Cancer According to the Compound Type and Developmental Stage of Drug
Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Stomach Cancer According to the Compound Type and Developmental Stage of Drug
Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal
Stromal Cancer According to the Compound Type and Developmental Stage of Drug
Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck
Cancer According to the Compound Type and Developmental Stage of Drug
Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia
(general) According to the Compound Type and Developmental Stage of Drug
Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic
Leukemia According to the Compound Type and Developmental Stage of Drug
Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous
Leukemia According to the Compound Type and Developmental Stage of Drug
Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic
Lymphocytic Leukemia According to the Compound Type and Developmental Stage of
Drug
Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic
Myelogenous Leukemia According to the Compound Type and Developmental Stage of
Drug
Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer
According to the Compound Type and Developmental Stage of Drug
Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer
(general) According to the Compound Type and Developmental Stage of Drug
Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell
Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung
Cancer According to the Compound Type and Developmental Stage of Drug
Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma
(general) According to the Compound Type and Developmental Stage of Drug
Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma
According to the Compound Type and Developmental Stage of Drug
Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s
Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s
Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma
According to the Compound Type and Developmental Stage of Drug
Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma
According to the Compound Type and Developmental Stage of Drug
Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma
According to the Compound Type and Developmental Stage of Drug
Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic
Syndrome According to the Compound Type and Developmental Stage of Drug
Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According
to the Compound Type and Developmental Stage of Drug
Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal
Cancer According to the Compound Type and Developmental Stage of Drug
Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal
Cancer According to the Compound Type and Developmental Stage of Drug
Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer
According to the Compound Type and Developmental Stage of Drug
Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer
According to the Compound Type and Developmental Stage of Drug
Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer
According to the Compound Type and Developmental Stage of Drug
Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer
According to the Compound Type and Developmental Stage of Drug
Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer
According to the Compound Type and Developmental Stage of Drug
Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer
According to the Compound Type and Developmental Stage of Drug
Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general)
According to the Compound Type and Developmental Stage of Drug
Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma
According to the Compound Type and Developmental Stage of Drug
Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell
Cancer According to the Compound Type and Developmental Stage of Drug
Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer
According to the Compound Type and Developmental Stage of Drug
Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer
According to the Compound Type and Developmental Stage of Drug
Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer
According to the Compound Type and Developmental Stage of Drug
Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Australia
Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Canada
Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in China
Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Denmark
Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Germany
Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Israel
Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Japan
Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in South Korea
Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Spain
Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Switzerland
Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in Taiwan
Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by
Companies in United Kingdom
Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by
Company in USA
View Cart
